Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Haloperidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.98 |
| ▸ | HTR1A | P08908 | 3/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.98 |
| ▸ | HRH1 | P35367 | 3/20 | 0.98 |
| ▸ | HTR2C | P28335 | 2/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Haloperidol SCHEMBL28699132 | 0.99 | DRD2 (0.96) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL8264 | 0.99 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL5070670 | 0.99 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| SCHEMBL20254453 | 0.99 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL15545886 | 0.98 | DRD2 (0.98) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL8741248 | 0.96 | DRD2 (0.94) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| SCHEMBL11752117 | 0.95 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL20644145 | 0.95 | DRD2 (0.92) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL9507217 | 0.95 | DRD2 (0.92) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| SCHEMBL9054984 | 0.93 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2026-05-07 | — | — | US | claimed |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | THOMAS JEFFERSON UNIVERSITY | 2024-08-01 | — | — | US | claimed |
| CN-110325193-B | Novel medical use of compound III | 勃林格殷格翰国际有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-114129527-A | Miniature tablet and preparation method and preparation thereof | 北京微智瑞医药科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | UNIVERSITEIT GENT (BE) | 2021-06-15 | — | — | US | claimed |
| WO-2020143395-A1 | FLUPENTIXOL MELITRACEN TABLET AND PREPARATION METHOD THEREFOR | 广东赛烽医药科技有限公司 | 2020-07-16 | — | — | WO | claimed |
| US-20200087730-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2020-03-19 | — | — | US | claimed |
| US-20190328768-A1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2019-10-31 | — | — | US | claimed |
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2026-05-07 | — | — | US | disclosed |
| CN-120865064-A | Capric acid haloperidol hydrochloride crystal form and preparation method and application thereof | 四川尚锐生物医药有限公司 | 2025-10-31 | — | — | CN | disclosed |
| CN-120865064-A | Capric acid haloperidol hydrochloride crystal form and preparation method and application thereof | 四川尚锐生物医药有限公司 | 2025-10-31 | — | — | CN | disclosed |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | THOMAS JEFFERSON UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| CN-118265524-A | Controlled release formulation of flavonol methylphenidate and process for preparing the same | 苏什玛·保罗·伯利亚 | 2024-06-28 | — | — | CN | disclosed |
| CN-111747926-B | Improved synthetic process method of topiramate free base | 浙江华海药业股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20070196423-A1 | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent | MED INSTITUTE, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070196481-A1 | Sustained-release tablet composition | PHARMACIA CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070182055-A1 | Inline application of coatings | COOK INCORPORATED (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070043423-A1 | Intraluminal device with a hollow structure | MED INSTITUTE INC. (US) | 2007-02-22 | — | — | US | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |
| US-4086234-A | Process for the preparation of tertiary amines | G. D. SEARLE & CO. (US) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196481-A1 | Sustained-release tablet composition | SI, ABCB11, SLC2A9 | DRD2 2014/4885HTR2A 662/4885DRD3 1987/4885 |
| US-20200087730-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | DRD2 1041/4885HTR2A 76/4885DRD3 1378/4885 |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | DRD2 1041/4885HTR2A 76/4885DRD3 1378/4885 |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | TLR9, PLA2G4C, STING1 | DRD2 4807/4885HTR2A 3727/4885DRD3 4820/4885 |
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | IGF2BP3, RBM3, MORF4L1 | DRD2 4055/4885HTR2A 1336/4885DRD3 3581/4885 |
| US-20190328768-A1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | TLR9, PLA2G4C, STING1 | DRD2 4807/4885HTR2A 3727/4885DRD3 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.